Board of Directors
Cellana’s experienced Board of Directors enables our company to move into the future with confidence.
Dr. Raleigh is an experienced manager of large research organizations. He held key appointments as coordinator of the Earthquake Prediction Program of the US Geological Survey and as director, Lamont-Doherty Geological Observatory, Columbia University, one of the nation’s leading research institutions. From 1989 through 2003, Dr. Raleigh served as dean of the School of Ocean and Earth Science and Technology, University of Hawaii, one of the top three marine research institutions in the nation with an annual operating budget of more than $70 million. Dr. Raleigh received his Ph.D. in Geophysics from UCLA.
Mr. Black has more than 20 years in financial management and advisory roles and has served in senior-level finance roles for six publicly-traded companies. Mr. Black currently serves as the Chief Financial Officer of AltheaDx, a company that offers a full suite of services focused on molecular biomarker discover, assay development, assay validation and prospective/retrospective clinical trial testing in support of companion diagnostic development and commercialization. Prior to joining AltheaDx, Mr. Black served as Chief Financial Officer of Verenium Corporation, a Nasdaq-listed pioneer in the development and commercialization of high-performance enzymes for use in industrial processes. During his tenure at Verenium, Mr. Black has played a leadership role in nearly $400 million of strategic, equity, and debt financing transactions. Mr. Black’s prior experience includes serving as Executive Director of Accounting and Corporate Controller of Isis Pharmaceuticals, Inc. and Principal and Interim Financial Executive of Regent Pacific Management Corporation, a financial advisory firm through which he served as Vice President of Finance and Corporate Controller of Clarent Corporation and Vice President and Corporate Controller of Accelerated Networks, Inc. Mr. Black is a certified public accountant (inactive) and began his career with Ernst & Young LLP. Mr. Black graduated with a bachelor’s degree in business from the University of Arizona.
Dr. Anton has served as COO of Cellana since January 2015. He brings nearly 30 years of relevant experience to the company, including prior technology and business leadership roles at some of the industry’s most innovative companies. Prior to joining Cellana, Dr. Anton held the position of Executive Vice President and Chief Technology Officer at Joule in which he led the transition of Joule’s CO2-to-fuels technology into a commercial reality. Dr. Anton spent five years at Codexis in multiple leadership roles, including Senior Vice President of Bioindustrials, Chief Technology Officer and Senior Vice President of Process Development & Manufacturing. During his tenure, he oversaw development and commercial application of the company’s bioindustrial platform and led the global R&D and manufacturing organization. He previously spent 25 years at DuPont in multiple senior management positions across bioprocessing and biocatalysis, including the role of global business lead for development of DuPont’s advanced biofuel. Dr. Anton holds a BS in biochemistry from the University of California, Berkeley, and a PhD in biochemistry from the University of Minnesota.
He has more than 25 years of fundraising, management, business development and commercial experience in the biotechnology, pharmaceutical and diagnostic industries. He has held executive positions at both public and private companies, including Agouron Pharmaceuticals, Warner-Lambert, Pfizer, Anadys Pharmaceuticals, VentiRx Pharmaceuticals and Genoa Pharmaceuticals, representing some of the most successful in the pharmaceutical and biotechnology communities. Over the course of his career to date, Kamdar has accounted for deal transactions in excess of $1 billion and has raised in excess of $300 million from venture capital and public capital market sources. Kamdar serves as a member of the board of directors of Tobira Therapeutics, Genoa Pharmaceuticals and BIOCOM. Mr. Kamdar has an M.B.A. from Villanova University (Malvern, PA) and a B.S. in Biology from St. Joseph’s University (Philadelphia, PA).
Mr. Sabarsky has served as CEO of Cellana since April 2011. Prior to this he had been CFO and COO of the Company since 2008. Prior to joining the Company, from 2000 to 2007, he led the corporate development function at Diversa Corporation within the Finance and Accounting department and took on increasing levels of management responsibility, most recently as Vice President of Corporate Development and a member of the Executive Committee. Before Diversa, Mr. Sabarsky worked as an investment banker with Bear, Stearns & Co. Inc., where he focused on financings and mergers and acquisitions within the life sciences industry and was a lead banker on Diversa’s $200 million IPO in 2000. Prior to joining Bear Stearns he worked as a transactional attorney with Latham & Watkins LLP. Mr. Sabarsky has an A.B. in Biology and Political Science from Brown University, a J.D. from Harvard Law School, and an M.B.A. from the Rady School of Management at the University of California, San Diego. He is currently a member of the Board of Directors of the Algae Biomass Organization (ABO).